Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.

ABSTRACT:

Background

In this paper, our aim was to systematically evaluate published evidence of bone fracture risk associated with tamoxifen and aromatase inhibitors in women aged 65 and under, and diagnosed with nonmetastatic breast cancer.

Methods

We comprehensively searched MEDLINE, EMBASE and CINAHL databases from January 1997 through May 2015, and reference lists of the selected articles to identify English-language randomized controlled trials and cohort studies of fracture risk. Two independent reviewers screened articles and assessed methodological quality using Risk of Bias assessment for randomized controlled trials and the Newcastle-Ottawa Scale for cohort studies. Fracture risk was estimated as pooled risk ratios using a random-effects model and inverse variance method.

SUBMITTER: Tseng OL 

PROVIDER: S-EPMC5871065 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature